Sunshine Biopharma (SBFM) Non-Current Assets (2015 - 2026)

Sunshine Biopharma's Non-Current Assets history runs 12 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• Quarterly Non-Current Assets fell 33.13% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (down 33.13% YoY) and the FY2025 annual result came in at $3.2 million, down 29.79% from the prior year.
• Non-Current Assets was $3.1 million for Q1 2026 at Sunshine Biopharma, down from $3.2 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $4.7 million in Q1 2025 and bottomed at $1642.0 in Q2 2022.
• A 5-year average of $2.6 million and a median of $3.1 million in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets plunged 87.82% — and 2023, when it jumped 140662.06%.
• Sunshine Biopharma's Non-Current Assets stood at $1.9 million in 2022, then grew by 27.2% to $2.5 million in 2023, then soared by 86.98% to $4.6 million in 2024, then slipped by 29.79% to $3.2 million in 2025, then declined by 2.43% to $3.1 million in 2026.
• Business Quant data shows SBFM's Non-Current Assets at $3.1 million in Q1 2026, $3.2 million in Q4 2025, and $3.5 million in Q3 2025.